− Proceeds to advance portfolio of selective A3 adenosine receptor agonists through human proof-of-concept studies − − Company appoints Dr. Charles Cohen as Chief Scientific Officer − SAN DIEGO, January 6, 2020-- BioIntervene Inc., a privately-held biopharmaceutical company pioneering the development of first-in-class, selective A3 adenosine receptor (A3AR) agonists, today announced that it has entered into a $30 million Series A financing, led by MPM Capital.